Given a patient with macrocytic anemia (hemoglobin 9.8 g/dL, MCV 107 fL), low serum iron, low total iron‑binding capacity, elevated ferritin, normal vitamin B12 and folate, and a low‑normal free thyroxine with normal thyroid‑stimulating hormone, what is the most likely diagnosis and appropriate management?

Anemia of Chronic Disease with Possible Subclinical Hypothyroidism

This patient most likely has anemia of chronic disease (ACD) with a possible contribution from subclinical hypothyroidism, and management should focus on treating the underlying thyroid dysfunction with levothyroxine while investigating for occult chronic inflammatory conditions.

Diagnostic Interpretation

Iron Studies Pattern

The laboratory pattern is classic for anemia of chronic disease:

• Elevated ferritin (421.2 ng/mL) with low serum iron (45.7 μg/dL) and low TIBC (120.7 μg/dL) indicates iron sequestration due to chronic inflammation 1
• Transferrin saturation of 37.86% is above the 16% threshold, ruling out functional iron deficiency 1
• When ferritin is >100 μg/L and transferrin saturation is >16%, this pattern strongly suggests ACD rather than iron deficiency 1

Macrocytic Anemia Analysis

The MCV of 107.4 fL with hemoglobin 9.8 g/dL represents macrocytic anemia, but:

• Vitamin B12 (537 pg/mL) and folate (4.67 ng/mL) are both normal, excluding megaloblastic causes 2
• The guideline states that macrocytic anemia can be non-megaloblastic, caused by hypothyroidism, liver disease, or certain drugs 2

Thyroid Function Assessment

The low-normal free T4 (0.59 ng/dL, reference 0.7-1.85) with normal TSH (0.779 μU/mL) suggests:

• Subclinical or early hypothyroidism with inadequate thyroid hormone production
• Hypothyroidism is a well-established cause of macrocytic anemia independent of B12/folate deficiency 3, 4, 5, 6, 7, 8
• Studies show that 20-60% of hypothyroid patients develop anemia, with macrocytosis occurring in up to 55% of cases 4
• The macrocytosis can result from thyroid hormone deficiency itself, not nutritional deficit 4, 5

Combined Pathophysiology

This patient demonstrates:

1. Primary process: Anemia of chronic disease (elevated ferritin, low iron, low TIBC)
2. Contributing factor: Subclinical hypothyroidism causing macrocytosis
3. Mechanism: Thyroid hormones directly stimulate erythropoiesis and erythroid colony growth; their deficiency leads to decreased RBC production 4, 6, 9

Management Algorithm

Immediate Actions

1. Initiate levothyroxine therapy for the low free T4, even with normal TSH

   • Thyroid hormone replacement is essential as it directly stimulates erythropoiesis 6, 9
   • Studies show hemoglobin improves significantly within 1-3 months of correcting thyroid dysfunction 9

2. Obtain inflammatory markers (CRP, ESR) to confirm chronic inflammation

   • These are independent of iron metabolism and help establish ACD diagnosis 1
   • The elevated ferritin with low iron/TIBC already suggests inflammation, but quantification guides further workup

3. Check reticulocyte count/index

   • Low reticulocyte index (<1.0-2.0) confirms decreased RBC production, consistent with both ACD and hypothyroidism 2, 10
   • This distinguishes production defects from hemolysis or blood loss

Diagnostic Workup for Underlying Chronic Disease

Since ACD requires an underlying inflammatory condition:

• Screen for occult malignancy: Age-appropriate cancer screening, particularly gastrointestinal given the anemia severity 2
• Evaluate for chronic infections: HIV, hepatitis C, tuberculosis if risk factors present
• Assess for autoimmune conditions: ANA, rheumatoid factor, especially given thyroid dysfunction (autoimmune thyroiditis association)
• Consider inflammatory bowel disease: Particularly if any GI symptoms, as IBD commonly causes ACD 1

Follow-Up Strategy

1. Recheck CBC, iron studies, and thyroid function in 4-6 weeks after starting levothyroxine

   • Expect MCV to decrease with thyroid hormone replacement 5
   • Hemoglobin should rise if hypothyroidism is the primary contributor 9

2. If hemoglobin fails to improve after thyroid correction:

   • Intensify search for underlying chronic inflammatory disease
   • Consider bone marrow evaluation if no cause identified and anemia worsens
   • Reassess for functional iron deficiency if starting erythropoiesis-stimulating agents

Critical Pitfalls to Avoid

Do not treat with iron supplementation: The elevated ferritin (>100 μg/L) and adequate transferrin saturation (>16%) indicate iron is available but sequestered due to inflammation 1. Iron therapy will not improve anemia and risks iron overload.

Do not dismiss the low-normal free T4: Even with normal TSH, the free T4 at the lower limit of normal (0.59 vs. 0.7 ng/dL reference) in the context of macrocytic anemia warrants thyroid hormone replacement 3, 4, 8. The macrocytosis itself may be a manifestation of thyroid hormone insufficiency.

Do not assume B12/folate deficiency is excluded forever: While currently normal, monitor these levels if macrocytosis persists or worsens, as hypothyroidism increases risk of pernicious anemia 20-fold 4, 5. The MCV is not a useful discriminant for pernicious anemia in hypothyroidism 5.

Do not overlook the need for underlying disease investigation: ACD does not occur in isolation—the elevated ferritin with low iron/TIBC mandates searching for malignancy, chronic infection, or inflammatory conditions 2, 1.